Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD.
Margherita NosadiniMichael EyreThea GiacominiMassimiliano ValerianiMarida Della CorteAndrea D PraticòPietro AnnovazziRamona CordaniDuccio Maria CordelliGiovanni CrichiuttiGabriella Di RosaValentina DolcemascoloAnna FettaElena FreriPaolo GalloMatteo GastaldiTiziana GranataLuisa GrazianRaffaele IorioMartina LombardiniMonica MargoniSara MariottoSara MatricardiFederico MelaniNardo NardocciLaura PapettiAlice PassariniFrancesco PisaniChiara Po'Marco PuthenparampilFrancesca RagonaSalvatore SavastaSabrina SiliquiniIrene ToldoAlessandra TozzoEmanuela Claudia TurcoAntonio VaroneAlberto VogrigLuigi ZulianiSamuela BuginSara RossatoAlessandro OrsiniGaetano CantalupoMaria Margherita MancardiMichela Ada Noris FerilliThomas FoiadelliStefano SartoriPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
At first attack of pediatric MOGAD, early immunotherapy, longer duration of corticosteroid treatment, and abnormal optic nerves on MRI seem associated with lower risk of relapse, whereas higher disease severity is associated with greater risk of final disability (EDSS ≥ 1).